Literature DB >> 33075789

Efficacy and Safety of Intravenous Tramadol versus Intravenous Paracetamol for Relief of Acute Pain of Primary Dysmenorrhea: A Randomized Controlled Trial.

Nevein Kamal Ghamry1, Ahmed Said Ali2, Mohammad Abrar Shareef3, Abdulhadi A AlAmodi4, Mohamed Hamza1, Ahmed M Abbas5, Hammad Ali Fadlalmola6, Mahmoud Alalfy7,8, Ahmed Omar Mahmoud9, Yomna Islam1.   

Abstract

INTRODUCTION: Many pharmaceutical, surgical, and complementary medical interventions are used for primary dysmenorrhea treatment. However, no consensus has been reached about the most effective intervention.
OBJECTIVE: To compare the efficacy and safety of IV tramadol versus IV paracetamol in relieving acute pain of primary dysmenorrhea.
METHODS: This randomized controlled trial was conducted in a tertiary referral hospital and included 100 patients between 18 and 35 years old diagnosed with primary dysmenorrhea. Patients received either 1-g paracetamol or 100-mg tramadol in 100-mL normal saline as an IV infusion over 10 min. Pain intensity was measured by using a visual analog scale at 15, 30, 60 min, and 2 h. We recorded drug side effects and requirements for rescue analgesics.
RESULTS: Pain scores were significantly lower in the tramadol group compared with the paracetamol group at 15, 30, 60 min, and 2 h (p < 0.001). Fewer patients in the tramadol group needed rescue analgesics compared with the paracetamol group (p = 0.04). No significant differences were reported in side effects between both groups.
CONCLUSIONS: IV tramadol is superior to IV paracetamol in relieving acute pain of primary dysmenorrhea with a comparable side effect profile.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Paracetamol; Primary dysmenorrhea; Tramadol

Mesh:

Substances:

Year:  2020        PMID: 33075789     DOI: 10.1159/000510268

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

Review 1.  Moxibustion for Primary Dysmenorrhea: An Adjuvant Therapy for Pain Relief.

Authors:  Sian Pan; Shaohua Wang; Juan Li; Hanyu Yuan; Xiao Xue; Yu Liu; Zenghui Yue
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-27       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.